Evidence map›Paper›PMID 28939377›Full record

ReviewAdvanced drug delivery reviews2018

Nanoparticle-based local antimicrobial drug delivery.

Weiwei Gao, Yijie Chen, Yue Zhang, Qiangzhe Zhang, Liangfang Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed.

  1. Development ofDiscover nano · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Mechanism, Efficacy, and Safety of Natural Antibiotics.Antibiotics (Basel, Switzerland) · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiwei GaoDepartment of Nanoengineering, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Yijie ChenDepartment of Nanoengineering, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Yue ZhangDepartment of Nanoengineering, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Qiangzhe ZhangDepartment of Nanoengineering, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
Liangfang ZhangDepartment of Nanoengineering, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: zhang@ucsd.edu.

Funding

Nanotherapeutics for Ocular InfectionsR01EY025947 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C, ZHANG, LIANGFANG · 2015 to 2017
$1.1M
NEI NIH HHS R01 EY025947
6 · The paper itself

Abstract

Despite the wide success of antibiotics in modern medicine, the treatment of bacterial infections still faces critical challenges, especially due to the rapid emergence of antibiotic resistance. As a result, local antimicrobial treatment aimed at enhancing drug concentration at the site of infection while avoiding systemic exposure is becoming increasingly attractive, as it may alleviate resistance development. Meanwhile, therapeutic nanoparticles, especially liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles, are gaining traction to improve the therapeutic efficacy with many applications specifically focused on local antimicrobial treatment. This review highlights topics where nanoparticle-based strategies hold significant potential to advance treatment against local bacterial infections, including (1) promoting antibiotic localization to the pathogen, (2) modulating drug-pathogen interaction against antibiotic resistance, and (3) enabling novel anti-virulence approaches for 'drug-free' antimicrobial activity. In each area, we highlight the innovative antimicrobial strategies tailored for local applications and review the progress made for the treatment of bacterial infections.

Indexed as

Drug Delivery SystemsAnti-Bacterial AgentsBacteriaBacterial InfectionsHumansNanoparticlesAnti-Bacterial AgentsAntimicrobial treatmentBacterial infectionLocal deliveryNanomedicineNanoparticle

Identifiers

PMID28939377
PMCPMC5860926

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.